Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Furosemide controlled release - scPharmaceuticals

Next Previous
Drug Profile

Furosemide controlled release - scPharmaceuticals

Alternative Names: Furoscix; Furoscix Infusor - scPharmaceuticals; Furosemide injection - scPharmaceuticals; Furosemide micropump patch - scPharmaceuticals/Sensile Medical; sc2Wear furosemide Infusor - scPharmaceuticals/Sensile Medical; SCP-101; SCP-111

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator scPharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics; Symporter inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic heart failure
  • Preregistration Oedema

Most Recent Events

  • 29 Mar 2024 FDA assigns PDUFA action date of 31/03/2025 for Furosemide controlled release for Edema in patients with chronic kidney disease (CKD)
  • 13 Mar 2024 scPharmaceuticals intends to submit supplemental new drug application (sNDA) to the US FAD in April 2024 seeking expansion of the FUROSCIX indication to include patients suffering from chronic kidney disease (CKD)
  • 12 Dec 2023 scPharmaceuticals plans a pharmacokinetics and pharmacodynamics phase I trial in Heart failure (In volunteers) (SC, IV) in April 2024 (NCT06167707)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top